Nanoparticles for nasal vaccination
The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeabilit...
Gespeichert in:
Veröffentlicht in: | Advanced drug delivery reviews 2009-02, Vol.61 (2), p.140-157 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 157 |
---|---|
container_issue | 2 |
container_start_page | 140 |
container_title | Advanced drug delivery reviews |
container_volume | 61 |
creator | Csaba, Noemi Garcia-Fuentes, Marcos Alonso, Maria Jose |
description | The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance.
The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination. |
doi_str_mv | 10.1016/j.addr.2008.09.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66942723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X08002640</els_id><sourcerecordid>66942723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</originalsourceid><addsrcrecordid>eNqFkM1KAzEYRYMotlZfwIUUBHczfvmbScCNFP-g6EbBXUgzXyBlOqnJtODbO6UFd7q6m3PP4hBySaGkQKvbZWmbJpUMQJWgSwB5RMZU1axQTItjMh4gXQjQnyNylvMSgLK6glMyopoyyiWMyfWr7eLapj64FvPUxzTtbLbtdGudC53tQ-zOyYm3bcaLw07Ix-PD--y5mL89vczu54XjSvaFpExqrxxDZTlfOM0F1cohyMpqUUtlgVPuhMWGVY0GTz0DYaWUFLwAzyfkZu9dp_i1wdybVcgO29Z2GDfZVJUWrGb8X5ABV4JXegDZHnQp5pzQm3UKK5u-DQWza2iWZtfQ7Boa0GZoOJyuDvbNYoXN7-UQbQDu9gAOMbYBk8kuYOewCQldb5oY_vL_AGy5gDs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20384369</pqid></control><display><type>article</type><title>Nanoparticles for nasal vaccination</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</creator><creatorcontrib>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</creatorcontrib><description>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance.
The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2008.09.005</identifier><identifier>PMID: 19121350</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Intranasal ; Animals ; Antigen delivery ; Bioadhesion ; Drug Carriers - administration & dosage ; Drug Delivery Systems - methods ; Humans ; Mucosal immunity ; Nanoparticles ; Nanoparticles - administration & dosage ; Nasal administration ; Nasal Mucosa - immunology ; Nasal Mucosa - metabolism ; Transmucosal transport ; Vaccines - administration & dosage</subject><ispartof>Advanced drug delivery reviews, 2009-02, Vol.61 (2), p.140-157</ispartof><rights>2008 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</citedby><cites>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.addr.2008.09.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19121350$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Csaba, Noemi</creatorcontrib><creatorcontrib>Garcia-Fuentes, Marcos</creatorcontrib><creatorcontrib>Alonso, Maria Jose</creatorcontrib><title>Nanoparticles for nasal vaccination</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance.
The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</description><subject>Administration, Intranasal</subject><subject>Animals</subject><subject>Antigen delivery</subject><subject>Bioadhesion</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug Delivery Systems - methods</subject><subject>Humans</subject><subject>Mucosal immunity</subject><subject>Nanoparticles</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nasal administration</subject><subject>Nasal Mucosa - immunology</subject><subject>Nasal Mucosa - metabolism</subject><subject>Transmucosal transport</subject><subject>Vaccines - administration & dosage</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1KAzEYRYMotlZfwIUUBHczfvmbScCNFP-g6EbBXUgzXyBlOqnJtODbO6UFd7q6m3PP4hBySaGkQKvbZWmbJpUMQJWgSwB5RMZU1axQTItjMh4gXQjQnyNylvMSgLK6glMyopoyyiWMyfWr7eLapj64FvPUxzTtbLbtdGudC53tQ-zOyYm3bcaLw07Ix-PD--y5mL89vczu54XjSvaFpExqrxxDZTlfOM0F1cohyMpqUUtlgVPuhMWGVY0GTz0DYaWUFLwAzyfkZu9dp_i1wdybVcgO29Z2GDfZVJUWrGb8X5ABV4JXegDZHnQp5pzQm3UKK5u-DQWza2iWZtfQ7Boa0GZoOJyuDvbNYoXN7-UQbQDu9gAOMbYBk8kuYOewCQldb5oY_vL_AGy5gDs</recordid><startdate>20090227</startdate><enddate>20090227</enddate><creator>Csaba, Noemi</creator><creator>Garcia-Fuentes, Marcos</creator><creator>Alonso, Maria Jose</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090227</creationdate><title>Nanoparticles for nasal vaccination</title><author>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Intranasal</topic><topic>Animals</topic><topic>Antigen delivery</topic><topic>Bioadhesion</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug Delivery Systems - methods</topic><topic>Humans</topic><topic>Mucosal immunity</topic><topic>Nanoparticles</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nasal administration</topic><topic>Nasal Mucosa - immunology</topic><topic>Nasal Mucosa - metabolism</topic><topic>Transmucosal transport</topic><topic>Vaccines - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Csaba, Noemi</creatorcontrib><creatorcontrib>Garcia-Fuentes, Marcos</creatorcontrib><creatorcontrib>Alonso, Maria Jose</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Csaba, Noemi</au><au>Garcia-Fuentes, Marcos</au><au>Alonso, Maria Jose</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoparticles for nasal vaccination</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2009-02-27</date><risdate>2009</risdate><volume>61</volume><issue>2</issue><spage>140</spage><epage>157</epage><pages>140-157</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance.
The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19121350</pmid><doi>10.1016/j.addr.2008.09.005</doi><tpages>18</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0169-409X |
ispartof | Advanced drug delivery reviews, 2009-02, Vol.61 (2), p.140-157 |
issn | 0169-409X 1872-8294 |
language | eng |
recordid | cdi_proquest_miscellaneous_66942723 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Administration, Intranasal Animals Antigen delivery Bioadhesion Drug Carriers - administration & dosage Drug Delivery Systems - methods Humans Mucosal immunity Nanoparticles Nanoparticles - administration & dosage Nasal administration Nasal Mucosa - immunology Nasal Mucosa - metabolism Transmucosal transport Vaccines - administration & dosage |
title | Nanoparticles for nasal vaccination |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A41%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoparticles%20for%20nasal%20vaccination&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Csaba,%20Noemi&rft.date=2009-02-27&rft.volume=61&rft.issue=2&rft.spage=140&rft.epage=157&rft.pages=140-157&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2008.09.005&rft_dat=%3Cproquest_cross%3E66942723%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20384369&rft_id=info:pmid/19121350&rft_els_id=S0169409X08002640&rfr_iscdi=true |